Recent Finacing
Recent Raise
Nouscom is a clinical-stage immuno-oncology company developing viral vector-based Exovax neoantigen vaccines and Endovax tumor-selective oncolytic viruses for off-the-shelf and personalized cancer immunotherapies.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Nouscom.
